Houston location provides access to state-of-the-art equipment and support, and close proximity to world class academic research facilities within local university medical and science centers, as Company continues development of groundbreaking bioprinting technology CHICAGO – May 29, 2018 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for…

Agreement provides access to world class academic research facilities and resources, including sophisticated imaging and instrumentation capabilities, as Company continues development of groundbreaking bioprinting technology CHICAGO, Feb. 05, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has signed a Laboratory…

Pioneering biotech company seeks investors in innovative technology to enable the 3D bioprinting of human hearts viable for transplant; investors of $100,000 or more will witness initial heart transplant firsthand CHICAGO – February 1, 2018 – BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced…

BIOLIFE4D stands on the precipice of a technology breakthrough that we truly believe will alter the way potential partners and investors consider our company. From Day 1, we have done our best to outline a clear strategy so that our shareholders, partners and interested parties would understand our vision. From there, it has been on us…

It is with great pleasure that I announce the opening of BIOLIFE4D research labs at JLABS, within the Texas Medical Center, Houston. After several months of strategy planning, BIOLIFE4D is now positioned in the heart of the world’s largest medical center, Texas Medical Center. Houston is the mecca of heart research and is home to…

The last several months have been an incredible time for BIOLIFE4D. In February, we launched our equity crowdfunding campaign to help in our mission to 3D bioprint viable treatment alternatives to cardiac issues, like patches, valves, and full hearts for transplant. Our scientific achievements are progressing rapidly, and the media has certainly taken notice. We have…

Regulation A+ (Reg A+) is a funding option that feels tailor-made for high impact technologies like medtech. Never heard of it? That’s because it didn’t exist until 2015, when the Obama administration passed the JOBS Act. Before then, private companies could only seek backing from the wealthiest 2% of Americans — accredited investors. The new…

THE IDEA: Bioprinting fully functioning human hearts to be used for transplants THE AHA MOMENT: Up until seven years ago, Steven Morris owned a company that specialized in machining medical implants and surgical equipment. He became fascinated with 3D printing as a way to create prototypes faster and began to wonder if the same thing could…

It’s been 50 years since Dr. Christiaan Barnard performed the first successful human-to-human heart transplant in South Africa – a procedure that would forever change the way heart disease is treated. Over the last half-century we’ve seen continued innovation in organ transplantation, from tissue typing to the discovery of immunosuppressant drugs, leading to a longer…